Opinion
Video
Author(s):
A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Physical function and frailty measures offer distinct insights in patients with bladder cancer
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
FDA updates in urology: April 2025